MMI-0100 是一种细胞渗透性肽抑制剂，抑制丝裂原活化蛋白激酶活化蛋白激酶 II (MK2)。MMI-0100 在体内外减少内膜增生。MMI-0100 抑制 IL-6 表达而不影响 IL-8 表达。MMI-0100 抑制纤维化过程，例如静脉移植疾病。
货号:ajcx37892
CAS:1039342-24-9
分子式:C98H171N37O26
分子量：2283.64
溶解度:H2O : 100 mg/mL (43.79 mM; Need ultrasonic)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease[1].

Naphthofluorescein (compound 19) (0-10 μM; 24 hours) suppresses the HIF-1 reporter activity in a concentration-dependent manner. [1].MMI-0100 (0.25 and 0.5 mM; 24 hours) slightly increases cell proliferation in both cell types compared to control cells treated with 20 ng/ml TNF-α alone[1].MMI-0100 (1 mM) treatment also increases both EC (11%) and SMC (7%) proliferation as compared to control, this response is not as robust as that induced by treatment with 0.5 mM MMI-0100[1].MMI-0100 does not induce EC apoptosis at any dose[1].

MMI-0100 (100 μM; 28 days) inhibits intimal hyperplasia in a mouse vein graft model[1].

[1]. Akihito Muto, et al. Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. Vascul Pharmacol. Jan-Feb 2012;56(1-2):47-55.